Non-Plant-Touching Status and Federal Tax Treatment
Testing laboratories are licensed and regulated by the Cannabis Compliance Board but typically provide analytical services on samples rather than buying or selling cannabis themselves, which means they generally do not take title to the product they test. This distinction can support a different federal tax posture than a plant-touching operator, since Section 280E's deduction disallowance is tied to trafficking in a controlled substance, not to providing services to the industry.
We help lab operators document their service-based business model clearly, including sample intake and chain-of-custody procedures that show the lab never owns or sells cannabis, which supports the position that ordinary business expenses such as marketing, administrative payroll and facility rent remain deductible.
Depreciating Analytical Equipment and Facility Investment
Chromatography systems, mass spectrometers and other analytical instruments represent a significant capital outlay with specific useful lives, maintenance schedules and calibration requirements. We build fixed asset schedules that track acquisition cost, depreciation method and expected replacement timing, which supports both accurate financial reporting and long-term capital planning for equipment upgrades.
- Instrument acquisition cost and useful life tracking
- Calibration and maintenance cost budgeting
- Replacement cycle planning tied to capacity growth
Throughput-Based Costing and Client Profitability
Lab profitability hinges on sample volume relative to largely fixed equipment and staffing costs, so understanding cost per test by analysis type, whether potency, pesticide, heavy metal or microbial screening, is essential for setting contract pricing with cultivators and manufacturers. We build throughput-based costing models that reveal which test types and client relationships are genuinely profitable versus which are priced below true cost.
